Neurogenic inflammation and migraine: implications for the therapeutics
about
The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraineMigraine pathogenesis and state of pharmacological treatment optionsIdentification of specific calcitonin-like receptor residues important for calcitonin gene-related peptide high affinity binding.The extracranial vascular theory of migraine--a great story confirmed by the facts.Diencephalic and brainstem mechanisms in migraine.Therapeutic use of botulinum toxin in migraine: mechanisms of action.Pearls and pitfalls in experimental in vivo models of migraine: dural trigeminovascular nociception.Overexpression and purification of human calcitonin gene-related peptide-receptor component protein in Escherichia coliDynamics of calcitonin gene-related peptide-like cells changes in the lungs of two-kidney, one-clip rats.Patient outcome in migraine prophylaxis: the role of psychopharmacological agentsHypoxia facilitates neurogenic dural plasma protein extravasation in mice: a novel animal model for migraine pathophysiologyAerobic Exercise for Reducing Migraine Burden: Mechanisms, Markers, and Models of Change ProcessesPost-junctional facilitation of Substance P signaling in a tibia fracture rat model of complex regional pain syndrome type I.Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches.Animal models of headache: from bedside to bench and back to bedside.5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine.Animal models of chronic migraine.Therapeutic prospects for migraine: can paradise be regained?Migraine in mitochondrial disorders: Prevalence and characteristics.An update on migraine: current understanding and future directions.Diverse Physiological Roles of Calcitonin Gene-Related Peptide in Migraine Pathology: Modulation of Neuronal-Glial-Immune Cells to Promote Peripheral and Central Sensitization.Pathophysiology of Migraine: A Disorder of Sensory Processing.Heteroreceptors Modulating CGRP Release at Neurovascular Junction: Potential Therapeutic Implications on Some Vascular-Related Diseases.CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat.Acute migraine therapy: new drugs and new approaches.Large conductance calcium-activated potassium channels (BKCa) modulate trigeminovascular nociceptive transmission.Human mast cells release the migraine-inducing factor pituitary adenylate cyclase-activating polypeptide (PACAP).Vasoactive Intestinal peptide modulates c-Fos activity in the trigeminal nucleus and dura mater mast cells in sympathectomized rats.Dural neurogenic inflammation induced by neuropathic pain is specific to cranial region.The Rodent Tibia Fracture Model: A Critical Review and Comparison with the Complex Regional Pain Syndrome Literature.Migraine Therapy: Current Approaches and New Horizons.Targeted 5-HT1F Therapies for Migraine.Nitric oxide synthase, calcitonin gene-related peptide and NK-1 receptor mechanisms are involved in GTN-induced neuronal activationPurinergic Profiling of Regulatory T-cells in Patients With Episodic Migraine
P2860
Q27008834-BD5BA051-F1DC-44B6-8F19-C11BB6832B75Q30886663-D53DB8E1-AE57-4F6F-8282-73AD59E065DAQ33246847-48A9C1A1-9EFA-4087-81EB-31A176254895Q34166916-DCA0D750-5C1E-4C06-A85A-5EFBB38986C4Q34217686-0FEE6ED8-B8C4-4FF8-8C70-6FEB75781446Q34419654-0807F367-2C10-46EB-9294-AF4A80491F5DQ34720188-6DD9E135-2875-4E2D-B45C-46B9E3E68827Q35728979-3504E8A3-78DF-476E-8257-FBE5258D3AF6Q35959643-DC6B75E6-2265-4A8B-9C2E-9F296A1033E5Q36160565-330B2715-8F4D-40B6-9B3F-06DA430DD7FBQ36353546-237E7DC3-8C27-4034-9DC1-47236F5646D5Q36743908-4A6D8187-4AF9-4574-9449-BBBCFC441C40Q37253305-755FEA82-EB2F-43DC-B8C0-939775BFD8ADQ37686124-CBEAD8AC-5C11-4DD9-B1A6-3A4AEA6432DBQ37699421-9EEE4041-8524-4DDD-97A2-0E873E8D86CFQ37739587-78528D72-01DA-4800-B874-ED5BA05AB6A0Q38129436-9C35DE08-E29F-4490-9E31-8ABF670790D5Q38270467-895AB532-C143-42A6-846D-89A08BBC7816Q38392414-802C9BC3-5351-448F-9F41-009614959EA7Q38649655-AAD1CCAE-89F1-43F2-9CB5-01968E899041Q38742593-6D3F0576-16A4-4888-9069-1F2380EA932FQ38873658-83D1CA54-ED80-447E-9B47-4120EA94F8EAQ39127073-58AEF418-A670-4C01-BB7C-F7FC55C980D1Q41085676-C06A206F-9DCD-474D-B686-03D026206D82Q41139207-113D7B09-E754-4FD9-A6AB-1F3361ED799CQ41642373-F2EB7CDE-4817-42C5-AE22-C0DE9FEF9631Q43242903-6CBA2F6D-28F2-42C9-857A-1386B21898B1Q47441037-90666DF8-556C-44E5-B58E-827C05FF75AFQ48423560-C55CB4B8-E4AB-4392-B44B-06D1E1F09BDDQ50227033-0D6DCD66-27AA-4FAC-AB9D-870A5BA52D72Q52312548-1C7813E1-F67F-4195-9B30-223BA25AFFA4Q52581504-403DBB86-91C1-4BB2-899D-F1C173E78098Q52682101-3BB867B0-313E-4977-83F1-AB7E1793C6C2Q57023856-CFC343F0-6EBB-4B91-8F6A-D3D83D74B010Q57491949-F5A71609-EC6E-4CD4-9C9B-EAF7AD86F64E
P2860
Neurogenic inflammation and migraine: implications for the therapeutics
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Neurogenic inflammation and migraine: implications for the therapeutics
@ast
Neurogenic inflammation and migraine: implications for the therapeutics
@en
Neurogenic inflammation and migraine: implications for the therapeutics
@nl
type
label
Neurogenic inflammation and migraine: implications for the therapeutics
@ast
Neurogenic inflammation and migraine: implications for the therapeutics
@en
Neurogenic inflammation and migraine: implications for the therapeutics
@nl
prefLabel
Neurogenic inflammation and migraine: implications for the therapeutics
@ast
Neurogenic inflammation and migraine: implications for the therapeutics
@en
Neurogenic inflammation and migraine: implications for the therapeutics
@nl
P356
P1476
Neurogenic inflammation and migraine: implications for the therapeutics
@en
P2093
Stephen J Peroutka
P304
P356
10.1124/MI.5.5.10
P407
P577
2005-10-01T00:00:00Z